Publications by authors named "V J Casini"
Background: Inflammatory bowel disease (IBD) is a group of chronic multifactorial inflammatory disorders including two major entities: Crohn's disease (CD) and ulcerative colitis (UC). Preliminary evidence suggests that patients with IBD may be at increased risk of developing intestinal and extraintestinal cancers (EICs). Actually, little is known about the association between IBD and EICs, and there is ever-growing concern regarding the safety of immunomodulators and biological therapy, which may represent a risk factor for carcinogenesis.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to determine the prevalence of disease-related malnutrition (DRM) and micronutrient deficiencies in patients with inflammatory bowel disease (IBD), while also identifying related risk factors.
- Among the 295 IBD patients assessed, 23% were found to have DRM, with no significant difference between those with Crohn's disease and those with ulcerative colitis.
- Factors such as low body mass index (BMI), recent hospitalizations, and disease activity were linked to DRM, highlighting that malnutrition and micronutrient deficiencies are common in the IBD population and relate to health complications.
Article Synopsis
- A study compared the effectiveness of four biologic drugs—adalimumab, infliximab biosimilar, golimumab, and vedolizumab—used to treat ulcerative colitis (UC) in Italy, focusing on achieving continuous clinical remission (CCR).
- Researchers analyzed data from 416 UC patients treated from 2014 to 2019, measuring success based on a strict CCR definition over one year.
- Results showed similar CCR rates among the four drugs, with vedolizumab proving more effective for patients who had previously failed anti-TNFα treatments, while safety profiles were comparable across all drugs.
Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.
Clin Transl Sci
January 2022
Data regarding double switching from originator infliximab (IFX) to IFX biosimilars in inflammatory bowel diseases (IBDs) are lacking. The purpose of this study was to evaluate the safety and efficacy of switching from originator IFX to CT-P13 and subsequently to SB2 (double switch) in patients with IBD. Patients undergoing IFX-double switch in eight Centers in Lombardy (Italy) from November 2018 to May 2019 were retrospectively analyzed.
View Article and Find Full Text PDF